Trial Profile

Treatment of Steroid refractory Graft versus Host Disease with monoclonal antibody B T 5/9 (anti-CD26).

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Begelomab (Primary)
Indications Graft-versus-host disease
Focus Therapeutic Use
Acronyms ADN-GVHD vs BT 5/9

Most Recent Events

13 Mar 2020 Results(n=69; 28 from two prospective studies and 41 patients on a compassionate use study) assessing treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody, published in the Bone Marrow Transplantation
22 Aug 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com